Immunovant, Inc. Ratios

Ratios Mar2020 Mar2021 Mar2022 Mar2023 Mar2024 Mar2025
Profitability
EBT Margin 10,606.56%
EBIT Margin 10,506.56%
EBITDA Margin 10,506.56%
Net Margin 10,622.08%
FCF Margin 8,542.08%
Leverage & Solvency
Interest Coverage Ratio -105.07
Times Interest Earned -105.07
Valuation
Enterprise Value 2,082.11M1,571.46M641.34M2,020.11M4,694.42M2,902.92M
Return Ratios
Return on Sales 106.22%